The expanded indication, supported by a phase 2 open-label trial, includes children of all ages with CLN2 disease, regardless of whether they are symptomatic or asymptomatic.

Tiziana Life Sciences’ intranasal foralumab has shown potential in treating nonactive secondary progressive multiple sclerosis through innovative immune modulation.

Anvi Gadani, MD, assistant clinical professor of medicine at Medstar Georgetown University Hospital, discussed surgical and device-guided therapies for managing advanced Parkinson disease and essential tremor.

With the approved IND, it expands research efforts of equecabtagene autoleucel from other autoimmune conditions like myasthenia gravis and NMOSD.

NeurologyLive joins the CMSC in mourning the loss of founder and CEO,June Halper, MSN, APC-C, MSCN, FAAN.

In a study with 147 participants, SAGE-324 did not show a statistically significant dose-response relationship or improvement compared to placebo in patients with essential tremor.

Investigators found that in melanomas in particular, interleukin-6 blockade seems to be effective in the management of immune-related adverse events from immune checkpoint inhibitors.

Pending positive results from an early-stage trial, a mid-stage study evaluating MyoPAXon’s effect on other targeted muscles and muscle function will be initiated.

Treated patients demonstrated improvements on the Bayley-4 in cognition, communication, and motor function that exceeded those seen in natural history studies of Angelman syndrome.

The director of movement disorders at the Banner Sun Health Research Institute talked about recent, promising advancements for diagnosing atypical Parkinsonian disorders and the questions that remain.

Steve Hoffmann, MS, and Alessio Travaglia, PhD, provide commentary on a recently launched public-private partnership aimed at identifying biomarkers to better differentiate Parkinson disease from other related neurodegenerative disorders.

Antonella Favit-Van Pelt, MD, PhD, chief medical officer at Helius Medical Technologies, gave perspective on the clinical advantages of the company’s non-implantable device to treat gait in multiple sclerosis.

In the event that a patient inadvertently took a 0.25 mg dose rather than the intended 0.125 mg dose, they are advised to consult a physician.

LETM and AQP4-IgG seropositivity were strong predictors of spinal movement disorders, while MOG-IgG and African American race are protective factors.

The study highlights tocilizumab's potential benefits and safety, even during SARS-CoV-2 infection.

Across all studies, including 2 of the largest recorded for CIDP, patients unanimously demonstrated a preference for SCIG over IVIG.

Patricia Clark, CNP, a nurse practitioner at the Cleveland Clinic, talked about a specialized program for hospitalized patients with Parkinson disease that aligns hospital protocols with home medication regimens to improve care.

Here's some of what is coming soon to NeurologyLive® this week.

Amifampridine enhances neuromuscular transmission and relieves muscle weakness, showing promise for Lambert-Eaton myasthenic syndrome and other neuromuscular junction disorders.

Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath, explored 3 perspectives on self-managing multiple sclerosis (MS): a general consensus, insights from MS-Selfie, and a future technology-based model.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on progressive multiple sclerosis.

This article reviews emerging MRI, OCT, CSF, and blood biomarkers, highlighting their potential roles in improving MS patient management and prognosis.

It’s hard to be in medicine at the moment, and one day’s recognition is not enough. As your peer, I honor my fellow physicians today and every day.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 19, 2024.

The investigational therapy, which targets neurodegeneration, has shown promise in phase 2 and 3 studies of Alzheimer disease and Parkinson disease, with additional studies on the way.